ADP-ribosylation in Evasion, Promotion and Exacerbation of Immune Responses
Overview
Authors
Affiliations
ADP-ribosylation is the addition of one or more (up to some hundreds) ADP-ribose moieties to acceptor proteins. This evolutionary ancient post-translational modification (PTM) is involved in fundamental processes including DNA repair, inflammation, cell death, differentiation and proliferation, among others. ADP-ribosylation is catalysed by two major families of enzymes: the cholera toxin-like ADP-ribosyltransferases (ARTCs) and the diphtheria toxin-like ADP-ribosyltransferases (ARTDs, also known as PARPs). ARTCs sense and use extracellular NAD, which may represent a danger signal, whereas ARTDs are present in the cell nucleus and/or cytoplasm. ARTCs mono-ADP-ribosylate their substrates, whereas ARTDs, according to the specific family member, are able to mono- or poly-ADP-ribosylate target proteins or are devoid of enzymatic activity. Both mono- and poly-ADP-ribosylation are dynamic processes, as specific hydrolases are able to remove single or polymeric ADP moieties. This dynamic equilibrium between addition and degradation provides plasticity for fast adaptation, a feature being particularly relevant to immune cell functions. ADP-ribosylation regulates differentiation and functions of myeloid, T and B cells. It also regulates the expression of cytokines and chemokines, production of antibodies, isotype switch and the expression of several immune mediators. Alterations in these processes involve ADP-ribosylation in virtually any acute and chronic inflammatory/immune-mediated disease. Besides, pathogens developed mechanisms to contrast the action of ADP-ribosylating enzymes by using their own hydrolases and/or to exploit this PTM to sustain their virulence. In the present review, we summarize and discuss recent findings on the role of ADP-ribosylation in immunobiology, immune evasion/subversion by pathogens and immune-mediated diseases.
Zhang C, Feng J, Zhou X, Zhang J, Tao C, Zhou H Discov Oncol. 2024; 15(1):839.
PMID: 39724285 PMC: 11671460. DOI: 10.1007/s12672-024-01734-2.
Pathogenesis and clinical features of severe hepatitis E virus infection.
Orosz L, Sarvari K, Dernovics A, Rosztoczy A, Megyeri K World J Virol. 2024; 13(2):91580.
PMID: 38984076 PMC: 11229844. DOI: 10.5501/wjv.v13.i2.91580.
Juvenal G, Meinerz C, Ayupe A, Campos H, Reis E, Longo B Cell Biosci. 2024; 14(1):82.
PMID: 38890712 PMC: 11184896. DOI: 10.1186/s13578-024-01251-3.
A deep learning method to predict bacterial ADP-ribosyltransferase toxins.
Zheng D, Zhou S, Chen L, Pang G, Yang J Bioinformatics. 2024; 40(7).
PMID: 38885365 PMC: 11219481. DOI: 10.1093/bioinformatics/btae378.
Immunometabolic interference between cancer and COVID-19.
Consonni F, Durante B, Manfredi M, Bleve A, Pandolfo C, Garlatti V Front Immunol. 2023; 14:1168455.
PMID: 37063865 PMC: 10090695. DOI: 10.3389/fimmu.2023.1168455.